---
document_datetime: 2025-08-25 15:08:32
document_pages: 7
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/sunosi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: sunosi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.484437
conversion_datetime: 2025-12-24 21:03:33.282636
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Sunosi

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                  |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0026              | Update of sections 4.6 and 5.2 of the SmPC in order to update information on lactation and breast- feeding based on results from the post-marketing lactation study JZP110-401 listed as a category 3 study in the RMP. This was a Phase 4, open-label, single-dose study to evaluate the PK of solriamfetol | 10/07/2025                          |                                             | SmPC and PL                      | Update of sections 4.6 and 5.2 of the SmPC in order to update information on lactation and breast-feeding. For more information, please refer to the Summary of Product Characteristics. |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | in the breast milk and plasma of healthy postpartum women following oral administration of a 150 mg solriamfetol tablet. The Package Leaflet is updated accordingly. The RMP version 1.3 has also been submitted. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0023              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                               | 14/11/2024 | 13/01/2025 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Sunosi in the approved indication remains favourable, but recommended that one additional five-year renewal be required based on the following pharmacovigilance grounds: • Frequent MAH change and data transfer • The product information and the risk management plan have not been updated with new data arising from a completed lactation clinical trial within reasonable period of time. |
| IA/0027             | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                            | 10/12/2024 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| IB/0025             | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                                                            | 12/11/2024 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| PSUSA/10831 /202403 | Periodic Safety Update EU Single assessment - solriamfetol                                                                                                                                                                                                                                                                            | 03/10/2024 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

| PSUSA/10831 /202303   | Periodic Safety Update EU Single assessment - solriamfetol                                                                                                                                                                             | 26/10/2023   | n/a        |                        | PRAC Recommendation - maintenance   |
|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-------------------------------------|
| T/0022                | Transfer of Marketing Authorisation                                                                                                                                                                                                    | 21/08/2023   | 22/09/2023 | SmPC, Labelling and PL |                                     |
| IAIN/0020             | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                     | 13/06/2023   | n/a        |                        |                                     |
| IA/0019               | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                          | 22/03/2023   | n/a        |                        |                                     |
| IAIN/0018             | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 13/12/2022   | 22/09/2023 | Annex II and PL        |                                     |
| PSUSA/10831 /202203   | Periodic Safety Update EU Single assessment - solriamfetol                                                                                                                                                                             | 27/10/2022   | n/a        |                        | PRAC Recommendation - maintenance   |
| T/0016                | Transfer of Marketing Authorisation                                                                                                                                                                                                    | 26/08/2022   | 07/10/2022 | SmPC, Labelling and PL |                                     |
| IB/0017               | B.II.b.4.e - Change in the batch size (including batch size ranges) of the finished product - More than 10- fold increase compared to the originally approved batch size for immediate release (oral) pharmaceutical form              | 03/10/2022   | n/a        |                        |                                     |

<div style=\"page-break-after: always\"></div>

| IA/0015/G                     | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size   | 07/07/2022            | n/a            |                        | PRAC Recommendation - maintenance                         |
|-------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|----------------|------------------------|-----------------------------------------------------------|
| PSUSA/10831 /202109 IA/0013/G | Periodic Safety Update EU Single assessment - solriamfetol This was an application for a group of variations. B.II.e.4.a - Change in shape or dimensions of the                                                                                                                                                                                                                            | 07/04/2022 13/12/2021 | n/a 07/10/2022 | SmPC, Labelling and PL |                                                           |
| PSUSA/10831 /202103           | Periodic Safety Update EU Single assessment - solriamfetol                                                                                                                                                                                                                                                                                                                                 | 28/10/2021            | n/a            |                        | PRAC Recommendation - maintenance                         |
|                               | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale                                                                                                                                                                                                                                                                                | 05/10/2021            | 07/10/2022     | SmPC                   | To change the shelf-life in section 6.3 of the Summary of |
| IB/0011                       |                                                                                                                                                                                                                                                                                                                                                                                            |                       |                |                        |                                                           |

<div style=\"page-break-after: always\"></div>

|                     | (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |            |             | Product Characteristics from 4 to 5 years.                                                                                                                                                                                                                                                                                                 |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0009             | Update of section 4.8 of the SmPC in order to add hypersensitivity reactions to the list of adverse drug reactions (ADRs) following confirmation of a post marketing safety signal for hypersensitivity. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement editorial changes and to bring the PI in line with the latest QRD template version 10.2. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 01/07/2021 | 19/10/2021 | SmPC and PL | The list of adverse drug reactions in section 4.8 of the SmPC is updated following confirmation of a post marketing safety signal for hypersensitivity reactions which have occurred with one or more of the following: rash erythematous, rash, urticarial. For more information, please refer to the Summary of Product Characteristics. |
| PSUSA/10831 /202009 | Periodic Safety Update EU Single assessment - solriamfetol                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 09/04/2021 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                          |
| IA/0008             | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                             | 15/12/2020 | n/a        |             |                                                                                                                                                                                                                                                                                                                                            |
| IB/0006             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                                                                                                 | 18/11/2020 | n/a        |             |                                                                                                                                                                                                                                                                                                                                            |
| PSUSA/10831 /202003 | Periodic Safety Update EU Single assessment - solriamfetol                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 01/10/2020 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

| IA/0005/G   | This was an application for a group of variations. B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.f - Change in test procedure for the finished product - To reflect compliance with the Ph. Eur. and remove reference to the outdated internal test method and test method number B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the   | 21/09/2020   | n/a        |                   | dossier) - Deletion of a   |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------------|----------------------------|
| II/0004     | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 10/09/2020   | n/a        |                   |                            |
| IB/0003/G   | This was an application for a group of variations. B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size B.II.b.4.b - Change in the batch size (including batch size ranges) of the finished product - Downscaling                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 21/08/2020   | 19/10/2021 | SmPC and Annex II |                            |

<div style=\"page-break-after: always\"></div>

|         | down to 10-fold B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data) B.II.f.1.e - Stability of FP - Change to an approved stability protocol   |            |     |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IB/0001 | B.II.d.2.z - Change in test procedure for the finished product - Other variation                                                                                                                                                    | 30/03/2020 | n/a |